Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial

ConclusionNo association was observed between a reduced BMD and DRFS. Neither did we observe an impact of bisphosphonates on DRFS.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSION: Bone loss is common in women with BRCA mutations who undergo RRSO. PMID: 29422346 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
ConclusionsIn this single health system experience, women start antiresorptive drugs that are unnecessary in 15 –52%. These results highlight the nonuniformity in guideline recommendations, and this has implications for quality of care, cost-effectiveness, and value-of-care analyses for preventing fractures.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
CONCLUSION: The majority of older Medicare beneficiaries with breast cancer treated with AIs do not undergo appropriate bone mineral density evaluation. PMID: 28267392 [PubMed - as supplied by publisher]
Source: JOP - Category: Gastroenterology Authors: Tags: J Oncol Pract Source Type: research
We examined the cost-effectiveness of dual energy X-ray absorptiometry (DXA) with antiresorptive (AR) therapy compared with fracture risk assessment, lifestyle advice, and vitamin supplementation. We used a hypothetical Markov cohort model of lifetime duration for 60-year-old women with early stage breast cancer receiving AIs. The data to inform the model came from medical literature, epidemiological reports, and costing data sets. Two eligibility scenarios for AR therapy were considered: (A) osteoporosis and (B) osteopenia or osteoporosis. The main outcomes were incremental cost per quality-adjusted life years gained and ...
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research
This article first appeared on the Golden Girls Network blog. Earlier on Huff/Post50: -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
Background. Elevated fasting blood glucose (FBG) in Latina women has been identified as a risk factor for osteoporosis, independent of history of breast cancer. Elevated FBG, a sign of poor glycemic control among Latina women has been shown to increase bone resorption and subsequent bone loss over time. Treatment for breast cancer can also result in significant decreases in bone mineral density (BMD), which may be further exacerbated by the premature onset of menopause. Decreases in estrogen associated with the onset of menopause and hormonal therapy have been shown to accelerate bone loss in women.Purpose. The purpose of ...
Source: Cancer Prevention Research - Category: Cancer & Oncology Authors: Tags: Quality of Life/Late Effects/Survivorship: Poster Presentations - Proffered Abstracts Source Type: research
Conclusions Although there is evidence of negative impact of the aromatase inhibitors on bone, our data still show a poor application of the recommendations in order to prevent osteoporosis related to the administration of these drugs. Part of the problem is the mixed literature on diagnosis and management of osteoporosis. Also medicare covers for a DEXA scan only once very two years. The national compliance for managing AI induced bone loss is very low which points out tthat this is a global problem. Our suggestion is a more active implementation of the guidelines, also by means of a greater collaboration between the onco...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Conclusions: The incidence of AIMSS in our review was 41%. Patients treated in the metastatic setting may have a lower rate of AIMSS. Our cohort revealed that more recent menopause did seem to be a risk factor. Baseline osteoporosis and osteoporosis treatments have a potential association to be explored. Management options included switching between AIs, temporary discontinuation, and NSAID treatment. Updated analysis will be presented. canres;75/9_Supplement/P3-12-09/TBL1T1tbl1 Potential risk factors for the development of AIMSS CharacteristicN(-)Arthralgia N(%)(+)Arthralgia N(%)p-value Type of AI Used Anastrozole 204 112...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
We examined the cost-effectiveness of dual energy X-ray absorptiometry (DXA) with anti-resorptive (AR) therapy compared with fracture risk assessment, lifestyle advice, and vitamin supplementation. We used a hypothetical Markov cohort model of lifetime duration for 60-year-old women with early stage breast cancer receiving AIs. The data to populate the model came from the published medical literature, epidemiological reports, and national costing datasets. Two eligibility scenarios for AR therapy were considered: (A) osteoporosis, and (B) osteopenia or osteoporosis. The main outcomes were incremental cost per quality-adjus...
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research
Conclusions These null case–control findings challenge the clinical assumption that osteoporosis is highly prevalent among all breast cancer survivors, providing foundational evidence to support differences by race/ethnicity and body weight. Implications for Cancer Survivors Routine bone density testing and regular patient–provider dialogue is critical in overweight/obese AA breast cancer survivors to ensure that healthy lifestyle factors (e.g., ideal weight, regular weight-bearing exercises, dietary adequacy of calcium and vitamin D) support optimal skeletal health.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | DEXA Scan | Orthopaedics | Osteoporosis | PET Scan | Study | Tamoxifen